Verséa Health, Inc. Company Profile

Background

Verséa Health, Inc., founded in the fourth quarter of 2018 by Sean Fetcho, Steve Porada, and Colby Fox, is a transformative healthcare company headquartered in Tampa, Florida. The company is dedicated to revolutionizing healthcare by promoting Proactive Health, Preventive Care, and Precision Medicine. Verséa Health's mission is to deliver innovative diagnostics, ophthalmic solutions, and groundbreaking discoveries, aiming to empower individuals to take control of their well-being.

Key Strategic Focus

Verséa Health operates through three strategic business units:

Verséa Diagnostics: Provides rapid, point-of-care diagnostic solutions, in-office lab services, and consumer over-the-counter (OTC) diagnostics and home health products.

Verséa Ophthalmics: Delivers innovative ophthalmic diagnostics and therapeutic solutions to enhance clinical management and treatment decisions, leading to improved patient care.

Verséa Discovery: Utilizes proprietary technologies to advance personalized medicine, pharmaceutical drug development, and agricultural waste reduction.

The company's core objectives include offering affordable and accessible healthcare services, emphasizing prediction, prevention, and value. Verséa Health leverages strategic industry partnerships to build long-term relationships with healthcare providers and retail companies nationwide.

Financials and Funding

As of April 2026, Verséa Health has not publicly disclosed specific details regarding its funding history, total funds raised, recent funding rounds, or notable investors. The company has not announced any recent funding rounds or capital utilization plans.

Pipeline Development

Verséa Health has developed several key products:

Empowered Choice™: An FDA-approved, 1.5 mg Levonorgestrel tablet providing emergency contraception at an affordable price point. Launched in December 2025, it is available at select convenience stores, adult sexual health and wellness retailers, specialty retailers nationwide, and online.

Verséa Easy Lab™: A line of rapid, at-home, over-the-counter diagnostic tests offering instant results for pregnancy, ovulation, colorectal cancer screening (iFOBT), and a six-panel drugs of abuse test. Launched in August 2023, these tests are sold at various retail locations.

Discount Rx Card and App: Introduced to provide consumers with discounts of up to 80% on prescription drugs at over 60,000 pharmacies across the U.S. The card is available for free download as an app.

Technological Platform and Innovation

Verséa Health distinguishes itself through several proprietary technologies and innovative approaches:

Proprietary Technologies: The company holds exclusive global licenses and five patents, with several more pending, covering private-labeled brands and proprietary digital and capital equipment assets.

Scientific Methodologies: Verséa Health employs advanced molecular laboratory testing, offering a comprehensive "business in a box" approach for physician office laboratories (POLs). This includes supply chain management, state-of-the-art technology, experienced staffing, validation and compliance, revenue cycle management, credentialing, laboratory information systems, and logistics.

Leadership Team

Verséa Health's leadership team comprises experienced professionals:

Sean Fetcho: Co-founder and Chief Executive Officer. Prior to Verséa, Sean launched and oversaw multiple successful print and digital publications targeting oncology, pain management, and cardiology professionals. He also co-founded a packaging company that extends the shelf-life of perishables while eliminating foodborne pathogens during transit.

Steve Porada: Co-founder and Chief Growth Officer, President of Verséa Discovery. With over 30 years in pharmaceutical research and commercialization, Steve has held various sales, marketing, and commercialization positions at pharmaceutical and medical device companies. He co-founded Aventine Co., a startup medical marketing and communications company focused on pain management, and conceptualized and founded PAINWeek, which was sold to Tarsus, a publicly traded company on the London Stock Exchange.

James M. Olin: Chief Commercial Officer and President of Verséa Diagnostics. Jim has over 25 years of leadership experience in brand marketing, sales, commercial development, and general management. He has held senior executive positions in multiple high-growth entrepreneurial and private equity-backed companies, building brands and commercial teams across diverse industries, including health and beauty, personal care, nutritional supplements, and integrative health.

Dr. Toby Moeller-Bertram: Chief Medical Officer of Verséa Discovery. Dr. Moeller-Bertram is double-board certified in Anesthesiology and Pain Management. He has served as an associate clinical professor of anesthesiology and psychiatry and as the director of clinical pain research at the University of California San Diego. He is also the director of research with Vitamed Research, LLC., conducting research projects and trials in the field of pain and neurosciences.

Robin Brooks: President of Verséa AgroTech. Robin has over 20 years of experience in mergers and acquisitions, strategic management, and implementing proprietary technologies to increase sales, efficiencies, profitability, and sustainability. She served as CEO of Brooks Food Group, operating two manufacturing plants and generating over $100 million in revenue. Robin holds a BA in economics from Smith College and a Master of Management from Kellogg Graduate School of Management.

Lisa Sawmiller: Director of Business Development. Lisa has over 30 years of experience in talent acquisition, employee relations, performance management, and benefits administration. She has worked for diverse industry leaders, including Rooms to Go, UnitedHealth Group, WellCare Health Plans, Inc., and Kelly IT Resources. Lisa holds a Bachelor of Science in Human Resource Management from Syracuse University and is an active member of the Society of Human Resource Management (SHRM).

Chelsea Keys: Operations & Compliance Director. Chelsea has over 10 years of administrative and operational experience, specializing in standardization and process improvement. She has been instrumental in facilitating Verséa's rapid growth and has been recognized for her ability to multitask and her strong work ethic. Chelsea holds a BS in Biomedical Sciences from the University of South Florida.

Noelle Rodriguez: Director of Business Development & Strategy, Verséa Discovery. Noelle has over 12 years of experience in healthcare, spanning clinical, sales, and management roles. She has a background in diagnostic imaging and health sciences from Quinnipiac University and is a board-certified radiologic technologist.

Ani Sierra: Senior Director of Business Development & Strategy, Verséa Diagnostics. Ani has over 18 years of experience in finance and healthcare, including managing a $3 billion portfolio at BMI Companies. She holds a BSc in Applied Statistics and Actuarial Science from the London School of Economics.

Austin White: Head of Business Development & Strategy. Austin has over 35 years of senior leadership experience, achieving exponential revenue and profit growth for Fortune 500 businesses across various industries. He has been involved in the U.S. healthcare and telehealth markets since 2010, focusing on providing affordable access to quality healthcare.

Competitor Profile

Market Insights and Dynamics

The healthcare industry is experiencing significant growth, driven by advancements in diagnostics, therapeutics, and personalized medicine. Companies like Verséa Health are well-positioned to capitalize on this trend by offering innovative solutions that enhance patient care and improve health outcomes.